Skip to main content
Premium Trial:

Request an Annual Quote

NJ's Reproductive Medicine Associates Licenses GeneGo's MetaCore

NEW YORK (GenomeWeb News) - GeneGo today said it has licensed its MetaCore technology to the Reproductive Medicine Associates of New Jersey.
The facility will use the tool to analyze gene-expression data in research and in their clinic. Julie Bryant, vice president of business development at GeneGo, said this is the first time MetaCore will be used by health-care practitioners instead of pharmaceutical companies or academic groups.
Financial details for the multi-year agreement were not disclosed.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.